Eflornithine oral - Orbus Therapeutics

Drug Profile

Eflornithine oral - Orbus Therapeutics

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orbus Therapeutics
  • Class Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Anaplastic astrocytoma

Most Recent Events

  • 25 May 2017 Chemical structure information added
  • 26 Sep 2016 Eflornithine oral - Orbus Therapeutics receives Orphan Drug status for Anaplastic astrocytoma in USA
  • 01 Jul 2016 Phase-III clinical trials in Anaplastic astrocytoma (Combination therapy, Second-line or greater) in USA (PO) (NCT02796261)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top